Stock Analysis of Tcr2 Therapeutics Inc (TCRR)

Loading ...

Birds's Eye

Technical Analysis of Tcr2 Therapeutics Inc

Stock Analysis of Tcr2 Therapeutics Inc (TCRR) - Birds Eye View

1W 2W 1M 3M 1Y 2Y 5Y

Overview

Code	TCRR
Close	1.48
Change	-0.090 / 5.73 %
Volume	3753.35 K
Vol Change	3364.90 K / 866.22 %
Industry	Biotechnology
Sector	Healthcare

AIO Strength Index

Technical Strength	Strong Bearish
Growth Index	Low Growth Stock
Value Index	Poor Value Stock
Profitability Index	Poor Profitability Stock
Stability Index	Low Stability Stock

Fundamental View of Tcr2 Therapeutics Inc

PE (TTM)

-0.352

Very Poor

Price / Book

0.311

Excellent

Price / Sales

0

Very Poor

Piotroski F Score

1.0

Very Poor

Market Cap

58107.32 K

Enterprise Value

75806.32 K

All Financial Ratio's

ROA (TTM)

-64.52

Very Poor

ROE (TTM)

-88.42

Very Poor

Net Margin (TTM)

0

Poor

Revenue

%

Net Profit

52.12 %

-151822.00 K

Debt to Equity

0.358

Very Good

Altman Z Score

-4.60

Very Poor

Quick Ratio

0

Poor

Cash Ratio

2.33

Good

Financial Statement Analysis

Highs/Lows of Tcr2 Therapeutics Inc

Period	Old price	Stock Return	S&P 500 Returns	High	Low	High Date	Low Date
One Week	1.75	15.43 %	1.54 %	1.77	1.48	25-May-23	31-May-23
Two Week	1.86	20.43 %	3.42 %	1.94	1.48	18-May-23	31-May-23
One Month	1.765	16.15 %	5.60 %	2.0399	1.48	08-May-23	31-May-23
Three Month	1.25	18.40 %	5.95 %	2.0399	1.152	08-May-23	03-Mar-23
Six Months	1.33	11.28 %	17.48 %	2.0399	0.821	08-May-23	23-Dec-22
One year	2.32	36.21 %	27.52 %	3.88	0.821	15-Aug-22	23-Dec-22
Two year	19.15	92.27 %	29.70 %	8.82	0.821	14-Oct-21	23-Dec-22

Technical View of Tcr2 Therapeutics Inc

RSI

27.34

Mild Bearish

MACD

-0.0357

Bullish

ADX

32.18

Mild Bearish

Super Trend

1.91

Bearish

Williams %R

-100.00

Mild Bullish

CCI

-189.08

Mild Bullish

Technical Analysis Deep Dive

EMA 5

1.60

Mild Bearish

EMA 15

1.73

Strong Bearish

EMA 50

1.69

Strong Bearish

EMA 100

1.63

Strong Bearish

SMA 100

1.51

Strong Bearish

SMA 200

1.64

Mild Bearish

SMA 5 / 20

1.63 / 1.83

Strong Bearish

SMA 15 / 50

1.80 / 1.69

Bullish

SMA 50 / 200

1.69 / 1.64

Strong Bullish

MA Analysis Deep Dive

Charts of Tcr2 Therapeutics Inc

Returns of Tcr2 Therapeutics Inc with Peers

Period / Stock	TCRR	DNAY	RPHM	NSPR
1 Week	-15.43%	11.73%	-3.31%	2.91%
1 Mth	-16.15%	1.52%	-1.13%	4.07%
3 Mth	18.40%	76.99%	6.06%	-13.04%
6mth	11.28%	5.82%	-74.11%	-21.08%
1 Year	-36.21%	-75.96%	-77.71%	30.68%
2 Year	-92.27%	-	-18.98%	3.84%
5 Years	-	-	-	-95.31%
charts	-

View All Together in Chart Inline Tile

Compare Fundamentals of Tcr2 Therapeutics Inc with Peers

Ratio / Stock	TCRR	DNAY	RPHM	NSPR
PE	-0.352	-1.11	-209.79	-16228.15
P/B	0.311	0.754	147.04	733.11
ROA	-64.52	-49.16	-62.09	-3.77
ROE	-88.42	-114.47	-70.09	-4.52
Debt To Equity	0.358	0.175	0.0037	0.0141
Revenue	0 %	11043.00 K 67.93 %	0 %	6205.00 K 20.00 %
Net Income	-151822.00 K 52.12 %	-38958.00 K 116.31 %	-67434.00 K 29.79 %	1292.00 K 106.99 %

Technicals of Tcr2 Therapeutics Inc with Peers

Technical / Stock	TCRR	DNAY	RPHM	NSPR	-
ADX	32.18	12.85	28.25	17.57
CMF	-0.436	0.096	-0.222	0.0349
MFI	13.14	68.59	18.43	39.49
RSI	27.34	59.61	54.03	57.37
MACD Abv Signal	False	True	False	True
Price Above 50 MA	False	True	True	True	-
Price Above 200 MA	False	True	False	False	-

About : Tcr2 Therapeutics Inc

Address : 100 Binney Street, Cambridge, MA, United States, 02142
Tel : 617 949 5200
URL : https://www.tcr2.com
Code : TCRR, ISIN : US87808K1060, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 14_Feb_2019
Employee Count : 58

TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Note : All Data Generated at the End of Trading Hours (EOD Data)